Clinical and molecular characteristics according to MN1 expression status in CN-AML patients 60 years of age or older
| Characteristic . | Low MN1 (n = 70) . | High MN1 (n = 70) . | P . |
|---|---|---|---|
| Age, y | .57 | ||
| Median | 66 | 69 | |
| Range | 60-81 | 60-81 | |
| Sex, no. (%) of males | 40 (57) | 32 (46) | .24 |
| Race, no. (%) | .49 | ||
| White | 66 (96) | 63 (93) | |
| Nonwhite | 3 (4) | 5 (7) | |
| Hemoglobin, g/dL | .16 | ||
| Median | 9.1 | 9.4 | |
| Range | 5.4-13.6 | 6.0-13.1 | |
| Platelets, × 109/L | .43 | ||
| Median | 63 | 72 | |
| Range | 20-271 | 11-850 | |
| WBC count, × 109/L | .15 | ||
| Median | 33.8 | 21.5 | |
| Range | 1.0-450.0 | 1.0-434.1 | |
| Blood blasts, % | 1.0 | ||
| Median | 45 | 49 | |
| Range | 0-96 | 0-99 | |
| BM blasts, % | .32 | ||
| Median | 71 | 64 | |
| Range | 15-97 | 7-96 | |
| Extramedullary involvement, no. (%) | 19 (28) | 15 (22) | .55 |
| FLT3-ITD, no. (%) | .59 | ||
| Present | 22 (31) | 26 (37) | |
| Absent | 48 (69) | 44 (63) | |
| FLT3-TKD, no. (%) | .08 | ||
| Present | 10 (14) | 3 (4) | |
| Absent | 60 (86) | 67 (96) | |
| CEBPA, no. (%) | .14 | ||
| Mutated | 6 (9) | 13 (19) | |
| Single mutated | 5 | 7 | |
| Double mutated | 1 | 6 | |
| Wild-type | 64 (91) | 57 (81) | |
| IDH1, no. (%) | .30 | ||
| Mutated | 10 (14) | 6 (9) | |
| Wild-type | 59 (86) | 63 (91) | |
| IDH2, no. (%) | .54 | ||
| IDH2-mutated | 13 (19) | 17 (24) | |
| R140-IDH2-mutated | 12 | 13 | |
| R172-IDH2-mutated | 1 | 4 | |
| Wild-type | 56 (81) | 53 (76) | |
| NPM1, no. (%) | < .001 | ||
| Mutated | 55 (79) | 26 (37) | |
| Wild-type | 15 (21) | 44 (63) | |
| TET2, no. (%) | .85 | ||
| Mutated | 19 (28) | 18 (26) | |
| Wild-type | 49 (72) | 51 (74) | |
| WT1, no. (%) | 1.0 | ||
| Mutated | 3 (4) | 3 (4) | |
| Wild-type | 67 (96) | 67 (96) | |
| BAALC expression,* no. (%) | < .001 | ||
| Low | 48 (73) | 24 (34) | |
| High | 18 (27) | 46 (66) | |
| ERG expression,* no. (%) | .23 | ||
| Low | 36 (55) | 30 (43) | |
| High | 30 (45) | 40 (57) | |
| miR-181a expression (continuous) | .04 | ||
| Median (log expression units) | 11.89 | 12.23 | |
| Range | 9.06-15.43 | 8.81-14.66 | |
| ELN risk group,† no. (%) | .03 | ||
| Favorable | 40 (57) | 26 (37) | |
| Intermediate-I | 30 (43) | 44 (63) |
| Characteristic . | Low MN1 (n = 70) . | High MN1 (n = 70) . | P . |
|---|---|---|---|
| Age, y | .57 | ||
| Median | 66 | 69 | |
| Range | 60-81 | 60-81 | |
| Sex, no. (%) of males | 40 (57) | 32 (46) | .24 |
| Race, no. (%) | .49 | ||
| White | 66 (96) | 63 (93) | |
| Nonwhite | 3 (4) | 5 (7) | |
| Hemoglobin, g/dL | .16 | ||
| Median | 9.1 | 9.4 | |
| Range | 5.4-13.6 | 6.0-13.1 | |
| Platelets, × 109/L | .43 | ||
| Median | 63 | 72 | |
| Range | 20-271 | 11-850 | |
| WBC count, × 109/L | .15 | ||
| Median | 33.8 | 21.5 | |
| Range | 1.0-450.0 | 1.0-434.1 | |
| Blood blasts, % | 1.0 | ||
| Median | 45 | 49 | |
| Range | 0-96 | 0-99 | |
| BM blasts, % | .32 | ||
| Median | 71 | 64 | |
| Range | 15-97 | 7-96 | |
| Extramedullary involvement, no. (%) | 19 (28) | 15 (22) | .55 |
| FLT3-ITD, no. (%) | .59 | ||
| Present | 22 (31) | 26 (37) | |
| Absent | 48 (69) | 44 (63) | |
| FLT3-TKD, no. (%) | .08 | ||
| Present | 10 (14) | 3 (4) | |
| Absent | 60 (86) | 67 (96) | |
| CEBPA, no. (%) | .14 | ||
| Mutated | 6 (9) | 13 (19) | |
| Single mutated | 5 | 7 | |
| Double mutated | 1 | 6 | |
| Wild-type | 64 (91) | 57 (81) | |
| IDH1, no. (%) | .30 | ||
| Mutated | 10 (14) | 6 (9) | |
| Wild-type | 59 (86) | 63 (91) | |
| IDH2, no. (%) | .54 | ||
| IDH2-mutated | 13 (19) | 17 (24) | |
| R140-IDH2-mutated | 12 | 13 | |
| R172-IDH2-mutated | 1 | 4 | |
| Wild-type | 56 (81) | 53 (76) | |
| NPM1, no. (%) | < .001 | ||
| Mutated | 55 (79) | 26 (37) | |
| Wild-type | 15 (21) | 44 (63) | |
| TET2, no. (%) | .85 | ||
| Mutated | 19 (28) | 18 (26) | |
| Wild-type | 49 (72) | 51 (74) | |
| WT1, no. (%) | 1.0 | ||
| Mutated | 3 (4) | 3 (4) | |
| Wild-type | 67 (96) | 67 (96) | |
| BAALC expression,* no. (%) | < .001 | ||
| Low | 48 (73) | 24 (34) | |
| High | 18 (27) | 46 (66) | |
| ERG expression,* no. (%) | .23 | ||
| Low | 36 (55) | 30 (43) | |
| High | 30 (45) | 40 (57) | |
| miR-181a expression (continuous) | .04 | ||
| Median (log expression units) | 11.89 | 12.23 | |
| Range | 9.06-15.43 | 8.81-14.66 | |
| ELN risk group,† no. (%) | .03 | ||
| Favorable | 40 (57) | 26 (37) | |
| Intermediate-I | 30 (43) | 44 (63) |
The median expression value was used as a cutpoint.
Favorable risk group consists of patients with CEBPA mutations or those who are FLT3-ITD-negative and harbor NPM1 mutations. Intermediate-I genetic group is composed of patients who are not in the Favorable group (ie, those with wild-type CEBPA and wild-type NPM1 with or without FLT3-ITD or mutated NPM1 with FLT3-ITD).